Pharmaceuticals, Biotechnology and Life Sciences
CTI BioPharma has announced the pricing of an underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock, offered at a price to the public of $2,000 per share of Series N-3 Preferred Stock (the “Offering”).
The U.S. Food and Drug Administration (FDA) has approved Alkermes’s two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
European Commission (EC) has approved the inclusion of Treatment-free Remission (TFR) data in the Novartis’s Tasigna (nilotinib) Summary of Product Characteristics (SmPC).
Bristol-Myers Squibb and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer treatment.
Novartis has updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Vertex Pharmaceuticals Incorporated has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund Orkambi (lumacaftor/ivacaftor).
BioMarin Pharmaceuticalsaid today that it got from the European Commission (EC) a grant for Brineura (cerliponase alfa), the first treatment approved in the European Union (EU) for tripeptidyl peptidase 1 (TPP1) deficiency.
Rebinyn got US FDA’s approval and is hoped to become an important tool for physicians to help patients manage their bleeds.
The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.
Drug delivery technology market grows from $1,179.20 billion to $1,669.40 billion at a CAGR of 7.2% from 2016-2021. Oral drug delivery segment is expected to account for the largest share while hospitals segment is expected to account for the largest share of the market and Asia is expected to be fastest-growing region.